Thermo Fisher Scientific announced the launch of the PPD™ CorEvitas™ Myasthenia Gravis (MG) Registry on November 17, 2025, after enrolling its first patient on November 10. The registry is the 14th entry in the company’s CorEvitas Clinical Registries program and will gather real‑world data from MG patients across the United States, tracking health conditions, safety, medication usage and treatment effectiveness.
The registry’s purpose is to provide a structured, longitudinal data set that will allow researchers and clinicians to study disease progression, evaluate the safety and effectiveness of existing and emerging MG therapies, and better understand the clinical and patient‑reported burden of the disorder. By collecting prospective data, the program supports long‑term regulatory‑grade evidence generation and advances real‑world research for a rare autoimmune disease that affects an estimated 70,000 people in the U.S. and is characterized by fluctuating muscle weakness and fatigue.
Thermo Fisher’s Q3 2025 financial results underscore the strategic importance of the registry launch. Revenue rose 5% year‑over‑year to $11.12 billion, and adjusted earnings per share climbed 10% to $5.79. The company’s adjusted operating margin expanded to 23.3% from 22.3% in the prior year, driven by strong demand in core segments and disciplined cost management. The registry initiative aligns with the company’s broader focus on real‑world evidence, positioning it to capture new revenue streams from post‑authorization safety studies and other regulatory‑grade research activities.
Segment‑level data show that Lab Products & Services generated $5.97 billion, Life Sciences & Analytical Instruments $2.59 billion, and Specialty Diagnostics $1.17 billion. The registry complements the Life Sciences segment, a key growth area, by providing high‑quality data that can accelerate drug development and support market access for new therapies.
Peter Wahl, Vice President and Global Head of Scientific Affairs for PPD CorEvitas Clinical Registries, said the MG Registry will enroll both ocular and generalized MG patients. “Data collected prospectively in this new clinical registry will enable us to study progression of disease and evaluate the safety and effectiveness of medications used in the treatment of generalized MG,” he said. “It will also help us understand the impact of the disease with respect to clinical burden as well as from the patient perspective.”
The launch strengthens Thermo Fisher’s position in the rare‑disease research market, creating opportunities for new revenue and enhancing its competitive stance. By expanding its real‑world evidence capabilities, the company is better positioned to support post‑authorization safety studies and to monetize data assets, reinforcing its strategy to become a leading provider of clinical research and real‑world evidence solutions.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.